LOS ANGELES, Nov. 23, 2015 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that it plans to host a conference call and webcast at
4:30 pm ET on Tuesday, November 24, 2015 to discuss the ICT-107
program in patients with newly diagnosed glioblastoma, including
recently reported updated phase 2 clinical trial results and the
design of the phase 3 registrational program. The conference call
and webcast will be hosted by Andrew
Gengos, President and CEO.
|
LIVE CALL:
|
(877) 853-5636
(toll-free); international dial-in: (631) 291-4544; conference code
89218581
|
|
|
|
WEBCAST:
|
Interested parties
who wish to listen to the webcast should visit the Investor
Relations section of ImmunoCellular's website at www.imuc.com,
under the Events and Presentations tab. A replay of the webcast
will be available one hour after the conclusion of the
event.
|
The conference call will contain forward-looking statements. The
information provided on the teleconference is accurate only at the
time of the conference call, and ImmunoCellular will take no
responsibility for providing updated information except as required
by law.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. The phase 3 registrational trial of lead product
candidate, ICT-107, a dendritic cell-based immunotherapy targeting
multiple tumor-associated antigens on glioblastoma stem cells, is
open for patient enrollment. ImmunoCellular's pipeline also
includes: ICT-121, a dendritic cell immunotherapy targeting the
CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
dendritic cell immunotherapy targeting antigens on ovarian cancer
stem cells; and the Stem-to-T-cell research program which engineers
the patient's hematopoietic stem cells to generate antigen-specific
cancer-killing T cells.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-host-conference-call-and-webcast-to-discuss-ict-107-program-in-newly-diagnosed-glioblastoma-on-november-24-2015-300183462.html
SOURCE ImmunoCellular Therapeutics, Ltd.